Objective: To compare the safety and efficacy of the dipeptidylpeptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes and inadequate glycemic control.
INTRODUCTION
Dipeptidylpeptidase-4 (DPP-4) inhibitors have a mechanism of action that is distinct from other oral glucose-lowering agents [1] . The DPP-4 inhibitor class of oral anti-diabetic agents selectively inhibits the DPP-4 enzyme that rapidly degrades two major incretin hormones, glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide [2] .
Scheen [2] reviewed DPP-4 inhibitors in 2011, analyzing the similarities and differences among members of the DPP-4 inhibitor class of oral antidiabetic agents, including their efficacy and safety profiles as monotherapy or in combination with metformin, a sulfonylurea (SU) and/or a thiazolidinedione, and insulin. The review demonstrated that, although DDP-4 inhibitors produce a similar reduction in glycosylated hemoglobin (HbA 1c ) levels compared with other existing classes of oral glucose-lowering agents, DPP-4 inhibitors offer several clinical advantages [3] . These include negligible risk of hypoglycemia, much lower than that observed with SUs, and weight neutrality, compared with the weight gain that is generally associated with SUs and thiazolidinediones [2] .
Previous indirect comparisons of the DPP-4 inhibitors in several published meta-analyses [4] [5] [6] [7] [8] have reported little or no difference between them with regard to efficacy, both as monotherapy and in combination with other anti-diabetic drugs, and the overall safety profile [2] . However, there are several important differences between the DPP-4
inhibitors with regard to their absorption, distribution, metabolism, and elimination, as well as potency and duration of action [2] .
These differences may, potentially, be clinically relevant, particularly in patients with renal or hepatic impairment, and in patients receiving combination therapy, especially those with cardiovascular disease taking multiple drugs [2, 9] . However, there is a lack of head-to-head clinical trials comparing DPP-4 inhibitors: a single clinical trial was identified in the Scheen review [2] . This 18-week trial compared the efficacy of saxagliptin 5 mg and sitagliptin 100 mg in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone [10] . We have conducted a similar review of DPP-4 inhibitors; as monotherapy compared with placebo, and as dual or triple therapy (where data were available) compared with metformin, SUs, metformin plus SU, pioglitazone, and insulin. Included studies were identified for all pharmacologic therapies for type 2 diabetes.
Following this wider review, we extracted data from RCTs in patients treated with a DPP-4 inhibitor and conducted mixed treatment comparison meta-analyses (MTCs) to demonstrate the relative treatment effects of each DPP-4 inhibitor compared with a common comparator, assessing the same four outcomes as reported by Esposito et al. [5] .
The aim of the MTCs was to test the hypothesis of no difference between the DPP-4
inhibitors with regard to glycemic control [mean HbA 1c change from baseline, proportion of patients achieving target HbA 1c (\7%)], number of patients with hypoglycemic events, and mean change from baseline in body weight.
METHODS
The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Systematic Literature Search
We conducted a systematic review of published literature to assess the comparative efficacy and safety of DPP-4 inhibitors compared to other oral and injectable anti-diabetic pharmacologic interventions, including insulin, in the treatment of patients with type 2 diabetes who were receiving monotherapy, dual, or triple therapy. The research question and eligibility criteria for this systematic review conformed to the following PICOS description [11] ; studies meeting these criteria were considered for inclusion:
• Population: patients of any age or sex with type 2 diabetes and insufficient glycemic control (including first-, second-, and thirdline treatment regimens).
• Intervention: any DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin), GLP-1 or sodium-glucose cotransporter 2 inhibitors, or pioglitazone used in the treatment of type 2 diabetes (as monotherapy, dual or triple therapy).
• Comparator: any pharmacologic antidiabetic treatment, placebo, or standard of care for diabetes.
• Outcome(s): HbA 1c (mean change from baseline and proportion of patients achieving HbA 1c target), fasting plasma glucose (FPG), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, body weight, and hypoglycemia and serious adverse events.
• Study type(s): blinded and open-label RCTs, health economic evaluation studies, systematic reviews, and meta-analyses.
Observational studies and retrospective analyses were not included.
Please note that this article focuses on analyses of DPP-4 inhibitors for the following outcomes: mean change in HbA 1c from baseline, proportion of patients achieving HbA 1c \7%, mean change from baseline in body weight, and number of patients experiencing a hypoglycemic event.
Published RCTs, health economic evaluation studies, systematic reviews, and meta-analyses, were identified from a systematic search of electronic databases with no publication date or language restrictions applied. Databases [15] for systematic reviews of health economic outcomes. All electronic databases were searched on November 30, 2012. Reference lists of selected systematic reviews and metaanalyses meeting the inclusion criteria were reviewed to identify further studies, including unpublished studies. 'Grey literature' searches were also conducted of relevant congresses (American Diabetes Association [16] , European Association for the Study of Diabetes [17] ,
International
Diabetes Federation [18] , Canadian Diabetes Association [19] , Health Technology Assessment (HTA) International [20] and International Society for Pharmacoeconomics and Outcomes Research [21] ), limited to the previous 3 years. Other appropriate sources searched included the ClinicalTrials.gov website of the US National Institutes of Health [22] , and HTA databases including those from the International Network of Agencies for Health Technology Assessment [23] , National Institute for Health and Care Excellence (NICE) [24] , National Institute for Health Research [25] , and Canadian Agency for Drugs and Technologies in Health [26] . A structured search string was employed, including terms for type 2/non-insulin dependent diabetes mellitus and drug therapy.
Specific filters for retrieving RCTs conducted in humans, meta-analyses, systematic reviews, and health economic evaluation studies were incorporated into the search string. The full search string is presented in Appendix 1 (Electronic Supplementary Material).
Any abstracts associated with full-text articles were identified. If more than one article presented data from the same study population, only data from the most recent full-text publication were included. If a conference abstract superseded a full-text publication, data from outcomes presented in the conference abstract that were not included in the full-text publication were utilized.
Study Selection
Identified articles were screened to ensure they met predetermined inclusion criteria. Each reviewer was provided with a checklist based on the inclusion/exclusion criteria specified in the systematic review protocol (Commercial in confidence), and a structured Microsoft Excel (Microsoft Corp, Redmond, WA, USA) spreadsheet was used to ensure uniformity of appraisal for each study. Initially, titles or abstracts (or both) of all identified citations were reviewed according to a first-pass checklist. Fulltext publications of the citations remaining after the first pass were then reviewed according to a second-pass checklist. A three-person team reviewed the articles at first and second pass, and an independent reviewer checked a random selection (10%) of filtered articles for consistency. A positive exclusion method was used, whereby studies for which there were insufficient information for exclusion remained in the review until a stage where it could be proven that they did not meet the inclusion criteria.
Although the systematic review included all pharmacologic treatments for type 2 diabetes, in this paper we report only the analyses of DPP-4 inhibitors.
Data Extraction
The Microsoft Excel spreadsheet designed to ensure uniformity of appraisal was subsequently used to capture all relevant data for included studies. All data extracted for meta-analysis were also independently reviewed and reviewers came to a consensus regarding the final data recorded for each study. Data input sheets for the meta-analyses, including data imputations, were also checked for accuracy by a second reviewer prior to conducting the analyses. Extracted data consisted of study characteristics [such as study design, duration, primary and secondary endpoints, study inclusion and exclusion criteria, treatment and dose (including schedule and strategy), and patient baseline characteristics (age, comorbidities, renal impairment, cardiovascular risk, concomitant medications, and disease duration)]. Extracted data were grouped such that information for different treatment regimens could be easily identified.
Assessment of Data for Meta-analysis
Studies were assessed to establish whether sufficient and appropriate data were reported for the relevant outcomes. Studies were excluded based on the following criteria:
article reported extension phase of an RCT already included; lack of common comparator (i.e., no connection within treatment network); inappropriate patient population (e.g., patients with adequate glycemic control, mixed population with type 1 diabetes); insufficient data for standard error imputation (i.e., patient numbers not given); cross-over study; and duplicate data.
Quality Assessment
Studies from which data were extracted were assessed for robustness as sources of information for inclusion in subsequent statistical analyses. Quality assessment was conducted according to the methods and assessment instruments recommended by the HTA authorities in France, Germany, Italy, Spain, UK, USA, and Canada. Hierarchical assessment of the risk of bias was conducted as recommended by the Institute for Quality and [28] , and qualityassessment criteria recommended by NICE (UK) in their single technology appraisal template [29] . Study quality was also independently reviewed. Clinical trials were also evaluated to assess whether they had been reported according to the Consolidated Standards of Reporting Trials [30] checklist. Study quality was not used as an inclusion/exclusion criterion or to weight individual studies in the metaanalyses.
Data Imputation
Where studies did not explicitly report standard errors, these were derived from available published information. If possible, standard errors were obtained from confidence intervals (CIs) and standard deviations (SDs); if these data were unavailable, they were derived from the p value referring to the change from baseline. If none of the above was available, standard errors were imputed using data from other wellreported studies, using methods outlined by the Cochrane Collaboration [31] . Alternatively, as a final option, if there was no other wellreported study, p values for the difference between treatments were used and the pooled SD applied to both arms. Mean changes from baseline values were derived by subtracting before and after values, if not explicitly stated.
Quantitative Analysis
Direct evidence was assessed by conducting random-effects meta-analyses in a frequentist setting in Stata (Version 12; StataCorp, College Station, TX, USA) for each DPP-4 inhibitor (as monotherapy, dual and triple therapy) against common comparator arms. In studies reporting results for multiple DPP-4 inhibitor doses, only data related to the licensed dose were included in the analysis. Data were presented as the effect estimate and 95% CI. Heterogeneity was assessed using the I 2 statistic, i.e., the percentage of the variability in effect estimates due to heterogeneity rather than sampling error. Interpretation of the I 2 statistic was in accordance with the Cochrane Collaboration recommendations [31] . For direct comparisons that reported I 2 values [30%, sensitivity analyses were considered and were conducted where outliers were identified to assess robustness of the pooled effect estimate.
Mixed treatment comparison meta-analyses
were also performed to demonstrate the relative treatment effects of each DPP-4 inhibitor (as monotherapy, dual or triple therapy) using a Bayesian framework and Markov chain Monte Carlo methods, which were fitted using the Bayesian software in WinBUGS (Medical  Research  Council  Biostatistics  Unit, Cambridge, UK) [32] . This allowed for direct evidence (within-trial comparisons between treatments) and indirect evidence (treatments within different trials with a common comparator) to be considered simultaneously.
Typically, models consisted of 100,000 iterations with a 50% burn-in sample.
Standard diagnostics tools were used to assess convergence to the stationary distribution. This included observing random walk plots for each node and assessment of the Gelman-Rubin diagnostic statistic. The rejection sampler followed the standard hierarchy of sampling methods in the WinBUGS program [32] . Initial values were generated randomly for different chains to assess the robustness of different starting values. Random-effects models were utilized to account for heterogeneity from varying study populations.
Mean changes from baseline in HbA 1c and body weight outcomes are both continuous measures. These were estimated using a vague prior normal distribution, allowing the data to have maximum leverage over the iterative process. Data were presented as a weighted mean difference between treatments.
Proportions of patients with HbA 1c \7% and hypoglycemic-event outcome measures are binomial (the outcome is either achieved or not). For this type of data, the probability of the outcome was modeled using a binomial distribution. Each pair of treatments was compared by estimating the odds ratio (OR) of the outcome. Each study within each randomeffects meta-analysis had a weight based on the within-study variation. It was assumed that each log OR had been sampled from a normal distribution and that the treatment effects were wholly exchangeable within studies.
Data for all DPP-4 inhibitor and comparator doses were included in the analyses for studies that reported multiple doses. All data were presented as an effect estimate and 95% credible interval, with 95% credible intervals that did not include zero deemed statistically significant. Overlapping 95% credible intervals were considered as evidence of no difference between treatments.
Mixed treatment comparison meta-analyses were conducted for absolute and relative (vs. comparator) treatment effects. Absolute treatment-effect calculations required an estimate for the efficacy of the comparator arm to be entered into the MTC. Directcomparison meta-analyses were conducted to obtain more accurate estimates of the comparator treatment effects (see Table 1 ).
Consistency Between Direct and Indirect

Data
The consistency of direct and indirect comparisons was assessed for nodes comparing [33] . Figure 1 shows the selection process for articles in the systematic review and meta-analyses.
RESULTS
Data Selection
Seventy-eight studies were excluded since they were deemed to contain insufficient or inappropriate data based upon criteria described in the ''Methods'' [see Appendix 2 for a listing (Electronic Supplementary Material)].
Sixty non-English articles proceeded to second pass, of which only two reported results of an RCT with a DPP-4 inhibitor. Both of these articles included the DPP-4 inhibitor, anagliptin, which is only licensed in Japan and was only reported in these two articles. Thus, it was not eligible for inclusion in the mixed treatment comparison network and was excluded from the analysis. metformin [10] . All RCTs were included in at least one of the analyses; each RCT could be used in multiple sets of analyses.
Characteristics of Included Studies
Quality assessment of studies for which data were extracted (Appendix 4, Electronic Supplementary Material) indicated two studies that represented high-quality or robust sources of information [34, 35] , as they were deemed to be of high quality by all quality-assessment criteria. However, it is worth noting that the majority of studies from which data were extracted and subsequently included in the statistical analyses were deemed to have three or fewer 'unclear' ratings, which could potentially indicate that the level of reporting was not sufficient to determine an accurate assessment of robustness. Ten studies were assessed as representing low-quality or nonrobust sources of information [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] ; however, all were deemed to have two or more 'unclear' ratings and only a single study [40] was included in the subsequent statistical analysis.
The majority of RCTs were double blind.
However, five articles reported data from openlabel RCTs [36, [47] [48] [49] [50] . Trial durations varied widely-from 4 weeks to 104 weeks. Two studies included an initial 12-week randomization stage followed by a 40-week extension [34, 51] . In the majority of trials, the primary outcome was mean change in HbA 1c from baseline to endpoint. However, eight trials reported coprimary outcomes to HbA 1c change from baseline [54, 59, 62, 64, [82] [83] [84] [85] , such as change from baseline in FPG, 2-hour postprandial glucose, BMI, body weight, fasting lipids, fasting plasma insulin, fasting insulin, fasting C-peptide, vital signs, and number/proportion of patients with adverse events, homeostatic model assessment-insulin resistance (b-cell function), and proportion of patients achieving HbA 1c \7%.
In five trials, HbA 1c change from baseline was not the primary outcome [36, 53, 68, 86, 87] . Instead, Individual study data for each of the four outcomes analyzed in the meta-analyses are summarized in Table 2 Table 2 Characteristics of included studies and summary of study results baseline to study endpoint were all reductions (i.e., improvements; Table 6 ); however, all reductions were non-significant. There was no significant difference between treatments in absolute mean body weight change from baseline for any DPP-4 inhibitor.
Study identifier References
DPP-4 Plus Metformin
In the direct-comparison meta-analysis, all DPP-4 inhibitors as dual therapy with metformin were significantly more effective in achieving a greater mean reduction from baseline in HbA 1c
and achieving a greater proportion of patients with HbA 1c levels \7% compared with metformin alone (Tables 3, 4 Table 5 Relative treatment effect mixed treatment comparisons Table 6 Absolute treatment effect mixed treatment comparisons (95% CI -0.01 to 0.20%), which is below the predefined criterion (\0.3%) for non-inferiority.
The relative MTCs showed that all DPP-4 inhibitors plus metformin were significantly more effective than metformin alone in reducing mean HbA 1c from baseline and achieving a higher proportion of patients with HbA 1c \7% (Table 5 ). Patients treated with alogliptin were statistically significantly more likely to achieve HbA 1c \7% than patients treated with saxagliptin; however, it should be noted that the 95% credible interval for There were no significant differences in mean change in body weight reported between DPP-4 plus metformin and metformin alone. No body weight data were available for saxagliptin. Absolute mean changes from baseline to study endpoint in mean HbA 1c levels were all reductions (i.e., improvements); however, none was statistically significant. Mean changes from baseline to study endpoint in body weight were also non-significant (Table 6 ).
DPP-4 Plus Sulfonylurea
In the direct-comparison analysis, linagliptin, saxagliptin, sitagliptin, and vildagliptin as dual therapy with SUs were significantly more effective in achieving a greater reduction in mean HbA 1c than SU alone (Tables 3, 4 In the MTCs, all DPP-4 inhibitors as dual therapy with SU were significantly more effective relative to SU alone in reducing HbA 1c levels ( There was no significant difference between treatments in absolute mean change from baseline to endpoint in HbA 1c or body weight for any comparison (Table 6 ). with metformin and SU, resulted in a significant mean change from baseline in body weight (Table 5 ). Change from baseline in body weight was not reported for vildagliptin triple therapy.
DPP-4 Plus Metformin Plus Sulfonylurea
There was no significant difference between sitagliptin, linagliptin, and vildagliptin in absolute mean change from baseline to endpoint in HbA 1c . Neither linagliptin nor sitagliptin treatment combination resulted in significant changes in body weight from baseline (Table 6 ).
DPP-4 Plus Pioglitazone
In the direct-comparison analysis, all DPP-4 inhibitors (except saxagliptin, for which no data were available) plus pioglitazone were significantly more effective than pioglitazone alone in achieving a greater reduction in HbA 1c from baseline and achieving a greater proportion of patients with HbA 1c levels \7% (Tables 3, 4) , although the I 2 statistics for alogliptin (86.6% and 54.6%, respectively) may represent substantial heterogeneity.
In the MTC, all DPP-4 inhibitors as dual therapy with pioglitazone were significantly more effective relative to pioglitazone alone in reducing mean HbA 1c levels from baseline. All DPP-4 inhibitors (except linagliptin) achieved a statistically significant greater proportion of patients with HbA 1c level \7% (Table 5) There was no statistically significant difference between treatments in absolute mean change from baseline to endpoint in HbA 1c or body weight for any comparison (Table 6 ).
DPP-4 Plus Metformin Plus Pioglitazone
As only a single study reported data for a DPP-4 inhibitor (alogliptin) as triple therapy with metformin plus pioglitazone [65] , meta- Compared with pioglitazone plus metformin dual therapy, triple combination therapy with alogliptin was not associated with a statistically significant gain in body weight or increased incidence of hypoglycemic events.
DPP-4 Plus Insulin
Data were only available for sitagliptin and vildagliptin. In the direct-comparison analysis, neither sitagliptin nor vildagliptin was statistically significantly more effective than insulin alone in achieving a greater reduction in mean HbA 1c from baseline or achieving a greater proportion of patients with HbA 1c levels \7% (Tables 3, 4 ). (Table 5 ).
There was no statistically significant difference between sitagliptin and vildagliptin in absolute mean change from baseline to endpoint in HbA 1c or body weight (Table 6 ).
DPP-4 Plus Metformin Plus Insulin
Only one study reported data for a DPP-4 inhibitor (sitagliptin) as triple therapy with metformin and insulin [36] ; meta-analyses were, therefore, not possible. mean change from baseline [88, 89] and two were identified for proportion of patients achieving HbA 1c \7% [89, 90] .
Sensitivity analyses were performed by investigating the effect of removing these outliers from the respective direct-comparison analyses. No further action was possible for analyses in which there were only two studies, as it was not possible to identify which study was likely to represent a 'true' estimate of the effect. Heterogeneity in the HbA 1c mean change from baseline analysis for linagliptin versus placebo was not examined as the I 2 statistic was borderline at 33% and there was no obvious outlier in the forest plot. studies with a randomized duration of \12 weeks; this current review did not exclude studies based upon duration (randomized study durations ranged from 4 weeks to 104 weeks). Despite these differences, the current study reached the same conclusion of no difference between all DPP-4 inhibitors across the four outcomes analyzed.
Strengths and Weaknesses of the Study
The strength of this analysis is its robust and transparent design. We conducted a systematic search and rigorous review of published RCTs of Studies from which data were extracted were assessed to establish if they represented a robust source of information. A potential weakness of the studies included in the statistical analyses was identified: the majority of studies were deemed to have between one and three 'unclear' assessments out of the seven assessment criteria. If the assessments were deemed to be 'unclear', it was not possible to differentiate between studies that had been poorly reported, and studies that were poorly conducted (i.e., of low quality, making it difficult to assess the quality/level of bias in the majority of the studies included in the analysis). Ten studies eligible for data extraction were deemed to be of low quality and, therefore, at a high risk of bias.
However, only one of these was eventually included in the statistical analyses, the remainder being excluded for other reasons.
Further, owing to the addition of a MESH/ Embase 'Drug Therapy' term restriction in the search string, it is possible that studies not indexed as drug therapy could have been 
